Brian Marek, MD
Ophthalmology · Blue Ash, OHNPI 1942543525
Payments from drug & device makers
Across 99 payments — averaging $54.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Haag-streit USA, Inc.$3K
- AbbVie$634
- Regeneron Healthcare Solutions, Inc.$373
- Bausch & Lomb Americas Inc.$221
- Alimera Sciences, Inc.$195
- Alcon$170
- plus $845 from 17 others
What the payments were for
- Consulting fees$3,00055%
- Food & beverage$2,44045%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Haag-streit USA, Inc. | 1 | $3,000 |
| AbbVie(2 entities) | 17 | $634 |
| Regeneron Healthcare Solutions, Inc. | 14 | $373 |
| Bausch & Lomb Americas Inc. | 11 | $221 |
| Alimera Sciences, Inc. | 10 | $195 |
| Alcon | 9 | $170 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $168 |
| Astellas Pharma US Inc | 4 | $109 |
| Novartis | 6 | $96 |
| Genentech USA, Inc. | 4 | $82 |
| Tarsus Pharmaceuticals, Inc. | 4 | $66 |
| Apellis Pharmaceuticals, Inc. | 3 | $66 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $44 |
| Sun Pharmaceutical Industries Inc. | 2 | $32 |
| Lombart Brothers, Inc. | 1 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Ocular Therapeutix, Inc. | 1 | $21 |
| Thea Pharma Inc. | 1 | $20 |
| Harrow Eye, LLC | 1 | $19 |
| Oyster Point Pharma, Inc. | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Ivantis, Inc | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$242
How this compares
$5,440 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 150 | $142,769 |
| ProlensaBromfenac Sodium | 119 | $40,384 |
| XiidraLifitegrast | 27 | $32,277 |
| Prednisolone Acetate | 428 | $18,948 |
| Alphagan PBrimonidine Tartrate | 20 | $10,653 |
| Cyclosporine | 34 | $10,445 |
| CombiganBrimonidine Tartrate/Timolol | 22 | $9,538 |
| TyrvayaVarenicline Tartrate | 14 | $9,500 |
| MieboPerfluorohexyloctane/Pf | 11 | $9,491 |
| RhopressaNetarsudil Mesylate | 16 | $8,097 |
| MoxifloxacinMoxifloxacin Hcl | 290 | $6,576 |
| Latanoprost | 733 | $5,920 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $3,518 |
| Brimonidine Tartrate | 256 | $3,257 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 149 | $2,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Combigan | $634 | $162,960192 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $221 | $41,76838 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $44 | $40,384119 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $18 | $9,50014 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $17 | $8,09716 claims |
| AlconSimbrinza | $170 | $3,51817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Blue Ash
- Lucas LindsellBlue Ash$1.3M
- James OsherBlue Ash$793K
- Arjun SoodBlue Ash$99K
- Alison EarlyBlue Ash$69K
- John PajkaLima$17.7M
- Justis EhlersCleveland$5M
- Lawrence SingermanBeachwood$3.9M
- Sunil SrivastavaCleveland$2.8M
- Daniel MillerCincinnati$2.3M
- Jonathan LassCleveland$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.